Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

7.5%

4 terminated/withdrawn out of 53 trials

Success Rate

82.6%

-3.9% vs industry average

Late-Stage Pipeline

28%

15 trials in Phase 3/4

Results Transparency

89%

17 of 19 completed trials have results

Key Signals

18 recruiting17 with results

Enrollment Performance

Analytics

Phase 2

17(34.7%)

Phase 3

9(18.4%)

Phase 1

7(14.3%)

Phase 4

6(12.2%)

Early Phase 1

6(12.2%)

N/A

4(8.2%)

49Total

Phase 2(17)

Phase 3(9)

Phase 1(7)

Phase 4(6)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (53)

Showing 20 of 53 trials

NCT07569926Phase 4Not Yet Recruiting

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Role: lead

NCT07568756Phase 2Not Yet Recruiting

Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation

Role: collaborator

NCT05555550Early Phase 1Recruiting

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Role: collaborator

NCT04689048Phase 1Recruiting

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

Role: collaborator

NCT06015295Not ApplicableRecruiting

A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy

Role: collaborator

NCT07432633Phase 1Recruiting

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Role: lead

NCT05678322Phase 3Active Not Recruiting

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

Role: collaborator

NCT07011342Not ApplicableRecruiting

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

Role: collaborator

NCT07164027Early Phase 1Recruiting

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Role: collaborator

NCT07455903Phase 2Not Yet Recruiting

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Role: collaborator

NCT07285057Phase 2Recruiting

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

Role: collaborator

NCT03995888Phase 1Completed

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Role: lead

NCT07393867Phase 2Not Yet Recruiting

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Role: collaborator

NCT06159335Phase 3Recruiting

18F-FLUC PET/MR in Patients With Brain Mets

Role: collaborator

NCT04018053Early Phase 1Active Not Recruiting

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Role: collaborator

NCT04175431Phase 2Recruiting

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Role: collaborator

NCT05553041Early Phase 1Recruiting

18F-Fluciclovine PET-MRI in High-grade Glioma

Role: collaborator

NCT05554302Phase 2Recruiting

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Role: collaborator

NCT05722925Phase 4Active Not Recruiting

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Role: collaborator

NCT06862856Recruiting

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

Role: collaborator